EUCTR2010-023759-27-DE进行中（未招募）不适用
A Phase III, Multicenter, Randomized, Open-label Clinical Trial Comparing the Efficacy and Safety of a Sitagliptin-Based Treatment Paradigm to a Liraglutide-Based Treatment Paradigm in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Monotherapy
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 600
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patient is =18 and =79 years of age with T2DM.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Patient has a history of type 1 diabetes mellitus or history of ketoacidosis.
- •2. Patient has been treated with any antihyperglycemic agent therapies other than metformin monotherapy within the prior 12 weeks of Visit 1/Screening Visit.
研究者
相似试验
进行中（未招募）
不适用
A Phase III, Multicenter, Randomized, Open-label Clinical Trial Comparing the Efficacy and Safety of a Sitagliptin-Based Treatment Paradigm to a Liraglutide-Based Treatment Paradigm in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Monotherapy - Non-Inferiority trial comparing two treatment regimens (sitagliptin & liraglutide)Type 2 Diabetes Mellitus (T2DM)MedDRA version: 12.1Level: PTClassification code 10067585Term: Type 2 diabetes mellitusEUCTR2010-023759-27-HUMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.600
进行中（未招募）
不适用
A Phase III, Multicenter, Randomized, Open-label Clinical Trial Comparingthe Efficacy and Safety of a Sitagliptin-Based Treatment Paradigmto a Liraglutide-Based Treatment Paradigm in PatientsWith Type2 Diabetes Mellitus Who Have Inadequate Glycemic Control onMetformin Monotherapy - NDPatients with T2DM andinadequate glycemic control (A1C =7.0% and =11.0%) on metformin monotherapyMedDRA version: 9.1Level: LLTClassification code 10053247EUCTR2010-023759-27-ITMERCK SHARP & DOHME CORP.600
进行中（未招募）
不适用
A Phase III, Multicenter, Randomized, Open-label Clinical Trial Comparing the Efficacy and Safety of a Sitagliptin-Based Treatment Paradigm to a Liraglutide-Based Treatment Paradigm in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin MonotherapyEUCTR2010-023759-27-LTMerck Sharp & Dohme Corp.600
进行中（未招募）
不适用
A Phase III, Multicenter, Randomized, Open-label Clnical Trial Comparing the Efficacy and Safety of a Sitagliptin-based Treatment Paradigm to a Liraglutide-Based Treatment Paradigm in Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Monotherapy - Non-inferiority trial comparing two treatment regimens (sitagliptin vs. liraglutide)EUCTR2010-023759-27-SKMerck & Co., Inc.600
进行中（未招募）
不适用
A Phase III, Multicenter, Randomized, Open-label Clinical Trial Comparing the Efficacy and Safety of a Sitagliptin-Based Treatment Paradigm to a Liraglutide-Based Treatment Paradigm in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Monotherapy - Non-inferiority trial comparing two treatment regimens (sitagliptin vs. liraglutide)Type 2 Diabetes Mellitus (T2DM)MedDRA version: 12.1Level: LLTClassification code 10067585Term: Type 2 diabetes mellitusMedDRA version: 12.1Level: PTClassification code 10067585Term: Type 2 diabetes mellitusEUCTR2010-023759-27-SEMerck Sharp & Dohme (Sweden) AB600